JP2005525385A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005525385A5 JP2005525385A5 JP2003577874A JP2003577874A JP2005525385A5 JP 2005525385 A5 JP2005525385 A5 JP 2005525385A5 JP 2003577874 A JP2003577874 A JP 2003577874A JP 2003577874 A JP2003577874 A JP 2003577874A JP 2005525385 A5 JP2005525385 A5 JP 2005525385A5
- Authority
- JP
- Japan
- Prior art keywords
- hydrochloride
- azabicyclo
- exo
- octane
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000002193 Pain Diseases 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 6
- 206010013663 drug dependence Diseases 0.000 claims description 6
- 208000011117 substance-related disease Diseases 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 230000004770 neurodegeneration Effects 0.000 claims description 5
- 208000030507 AIDS Diseases 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 208000019901 Anxiety disease Diseases 0.000 claims description 3
- 208000000094 Chronic Pain Diseases 0.000 claims description 3
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims description 3
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims description 3
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims description 3
- 206010059866 Drug resistance Diseases 0.000 claims description 3
- 208000012661 Dyskinesia Diseases 0.000 claims description 3
- 208000010412 Glaucoma Diseases 0.000 claims description 3
- 208000023105 Huntington disease Diseases 0.000 claims description 3
- 208000013016 Hypoglycemia Diseases 0.000 claims description 3
- 206010021143 Hypoxia Diseases 0.000 claims description 3
- 208000006264 Korsakoff syndrome Diseases 0.000 claims description 3
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims description 3
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims description 3
- 208000026072 Motor neurone disease Diseases 0.000 claims description 3
- 208000008238 Muscle Spasticity Diseases 0.000 claims description 3
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- 206010043118 Tardive Dyskinesia Diseases 0.000 claims description 3
- 208000009205 Tinnitus Diseases 0.000 claims description 3
- 208000000323 Tourette Syndrome Diseases 0.000 claims description 3
- 208000016620 Tourette disease Diseases 0.000 claims description 3
- 201000004810 Vascular dementia Diseases 0.000 claims description 3
- 208000005298 acute pain Diseases 0.000 claims description 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 3
- 230000036506 anxiety Effects 0.000 claims description 3
- 210000003169 central nervous system Anatomy 0.000 claims description 3
- 230000001684 chronic effect Effects 0.000 claims description 3
- 206010015037 epilepsy Diseases 0.000 claims description 3
- 230000003492 excitotoxic effect Effects 0.000 claims description 3
- 231100000063 excitotoxicity Toxicity 0.000 claims description 3
- 208000007386 hepatic encephalopathy Diseases 0.000 claims description 3
- 230000002218 hypoglycaemic effect Effects 0.000 claims description 3
- 230000007954 hypoxia Effects 0.000 claims description 3
- 208000014674 injury Diseases 0.000 claims description 3
- 230000007774 longterm Effects 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 230000004065 mitochondrial dysfunction Effects 0.000 claims description 3
- 201000006417 multiple sclerosis Diseases 0.000 claims description 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 3
- 201000000980 schizophrenia Diseases 0.000 claims description 3
- 208000018198 spasticity Diseases 0.000 claims description 3
- 231100000886 tinnitus Toxicity 0.000 claims description 3
- 230000008733 trauma Effects 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 12
- 229940099433 NMDA receptor antagonist Drugs 0.000 claims 2
- 125000004450 alkenylene group Chemical group 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 claims 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- UBAYTMLUKJFWKU-UHFFFAOYSA-N 1,3,3,5,6-pentamethyl-6-azabicyclo[3.2.1]octane Chemical compound C1C2(C)N(C)CC1(C)CC(C)(C)C2 UBAYTMLUKJFWKU-UHFFFAOYSA-N 0.000 claims 1
- KJNPYCPXGWCVRN-UHFFFAOYSA-N 1,3,3,5-tetramethyl-6-azabicyclo[3.2.1]octane Chemical compound C1C2(C)NCC1(C)CC(C)(C)C2 KJNPYCPXGWCVRN-UHFFFAOYSA-N 0.000 claims 1
- NTHBANFYFGMKNN-UHFFFAOYSA-N 5-ethyl-1,3,3-trimethyl-6-azabicyclo[3.2.1]octane Chemical compound C1C2(C)CNC1(CC)CC(C)(C)C2 NTHBANFYFGMKNN-UHFFFAOYSA-N 0.000 claims 1
- YIVWYYZYBLLGIR-UHFFFAOYSA-N 7,7,9,9-tetramethyl-1-azaspiro[4.5]decane Chemical compound C1C(C)(C)CC(C)(C)CC11NCCC1 YIVWYYZYBLLGIR-UHFFFAOYSA-N 0.000 claims 1
- AFRVUEQFUFKBNX-UHFFFAOYSA-N 8,10,10-trimethyl-6-azatricyclo[6.3.1.01,6]dodecane Chemical compound C1N2CCCCC22CC1(C)CC(C)(C)C2 AFRVUEQFUFKBNX-UHFFFAOYSA-N 0.000 claims 1
- GDSLUJLJBCXFRY-UHFFFAOYSA-N 8,8,10,10-tetramethyl-1-azaspiro[5.5]undecane Chemical compound C1C(C)(C)CC(C)(C)CC11NCCCC1 GDSLUJLJBCXFRY-UHFFFAOYSA-N 0.000 claims 1
- 201000006474 Brain Ischemia Diseases 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 208000001089 Multiple system atrophy Diseases 0.000 claims 1
- 229940127523 NMDA Receptor Antagonists Drugs 0.000 claims 1
- 201000008485 Wernicke-Korsakoff syndrome Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims 1
- 208000031237 olivopontocerebellar atrophy Diseases 0.000 claims 1
- 230000003287 optical effect Effects 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 4
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 2
- 206010008027 Cerebellar atrophy Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 description 2
- 240000007817 Olea europaea Species 0.000 description 2
- 229940049706 benzodiazepine Drugs 0.000 description 2
- 150000001557 benzodiazepines Chemical class 0.000 description 2
- 229960003920 cocaine Drugs 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 208000005264 motor neuron disease Diseases 0.000 description 2
- 229960002715 nicotine Drugs 0.000 description 2
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 2
- 229940005483 opioid analgesics Drugs 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36638602P | 2002-03-21 | 2002-03-21 | |
| PCT/GB2003/001236 WO2003080046A1 (en) | 2002-03-21 | 2003-03-21 | Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexane nmda, 5ht3, and neuronal nicotinic receptor antagoni sts |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005525385A JP2005525385A (ja) | 2005-08-25 |
| JP2005525385A5 true JP2005525385A5 (https=) | 2009-01-15 |
| JP4262606B2 JP4262606B2 (ja) | 2009-05-13 |
Family
ID=28454794
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003577874A Expired - Fee Related JP4262606B2 (ja) | 2002-03-21 | 2003-03-21 | Ｎｍｄａ、５ｈｔ３及び神経性ニコチンレセプターアンタゴニストとしてのアミノシクロヘキサンのアザ二環状、アザ三環状及びアザスピロ環状誘導体 |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US7022729B2 (https=) |
| EP (1) | EP1485086A1 (https=) |
| JP (1) | JP4262606B2 (https=) |
| KR (1) | KR100741257B1 (https=) |
| CN (1) | CN1638762A (https=) |
| AR (1) | AR039008A1 (https=) |
| AU (1) | AU2003216855B2 (https=) |
| CA (1) | CA2474637A1 (https=) |
| CO (1) | CO5611104A2 (https=) |
| EA (1) | EA007098B1 (https=) |
| GE (1) | GEP20063954B (https=) |
| IL (1) | IL164041A0 (https=) |
| MX (1) | MXPA04007755A (https=) |
| NO (1) | NO20044481L (https=) |
| PL (1) | PL372701A1 (https=) |
| TW (1) | TW200306189A (https=) |
| UA (1) | UA77778C2 (https=) |
| WO (1) | WO2003080046A1 (https=) |
| ZA (1) | ZA200406940B (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2483126T3 (es) | 2004-06-17 | 2014-08-05 | Merz Pharma Gmbh & Co. Kgaa | Formulaciones de formas de dosificación de neramexano |
| US20060205822A1 (en) * | 2004-12-22 | 2006-09-14 | Forest Laboratories, Inc. | 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect |
| EP2111858A1 (en) | 2008-04-25 | 2009-10-28 | EPFL Ecole Polytechnique Fédérale de Lausanne | Novel treatment for alzheimer's disease |
| US20090275597A1 (en) * | 2008-05-02 | 2009-11-05 | Forest Laboratories Holdings Limited | Methods of treating cns disorders |
| PE20130775A1 (es) * | 2010-05-27 | 2013-07-21 | Targacept Inc | Antagonistas no competitivos de receptores nicotinicos |
| RU2014122338A (ru) * | 2011-11-03 | 2015-12-10 | Таргасепт, Инк. | Неконкурентные модуляторы никотиновых рецепторов |
| JP6095122B2 (ja) * | 2012-01-25 | 2017-03-15 | 国立大学法人東北大学 | 脳機能改善剤 |
| PE20151727A1 (es) | 2013-03-14 | 2015-12-17 | Boehringer Ingelheim Int | Acido 2-aza-biciclo[2.2.1]heptano-3-carboxilico (bencil-ciano-metil)-amidas sustituidas inhibidores de catepsina c |
| KR102510588B1 (ko) | 2014-09-12 | 2023-03-17 | 베링거 인겔하임 인터내셔날 게엠베하 | 카텝신 c의 스피로사이클릭 억제제 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1153973A (en) * | 1966-03-14 | 1969-06-04 | Upjohn Co | alpha,alpha-Diphenyl-beta-Methyl-1-Azaspiro[4,5]Decane (and [4,4]Nonane)-1-Propanols |
| GB1472334A (en) * | 1973-07-14 | 1977-05-04 | Tanabe Seiyaku Co | 1-3-hydroxyphenyl-6-azabicyclo-3,2,1-octane derivatives and their use in pharmaceutical preparations |
| FR2451368A1 (fr) * | 1979-03-12 | 1980-10-10 | Lilly Co Eli | Phenylmorphanes, intermediaires et procedes de synthese, et leur utilisation therapeutique |
| DE3132020A1 (de) * | 1981-08-13 | 1983-03-03 | Basf Ag, 6700 Ludwigshafen | N-benzoyl-n'-phenylharnstoffe, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung von insekten und spinnentieren |
| JPS62297848A (ja) * | 1986-06-17 | 1987-12-25 | Konica Corp | ハロゲン化銀写真感光材料 |
| AU1161292A (en) | 1991-01-09 | 1992-08-17 | Smithkline Beecham Plc | Azabicydic and azatricydic derivatives, process and intermediates for their preparation and pharmaceutical compositions containing them |
| JP3134952B2 (ja) * | 1991-09-18 | 2001-02-13 | 東洋紡績株式会社 | 難撚性ポリエステル樹脂組成物の製造方法 |
| FR2693462B1 (fr) * | 1992-07-08 | 1994-09-30 | Cepbepe | Préparation de nouveaux dérivés amido-alcools et leurs applications en thérapeutique. |
| WO1994008964A1 (fr) * | 1992-10-16 | 1994-04-28 | Asahi Kasei Kogyo Kabushiki Kaisha | Derive de n-phenethylazepine et son utilisation |
| KR100224961B1 (ko) | 1994-08-18 | 1999-10-15 | 디. 제이. 우드 | 신경보호성 3-(피페리디닐-1)-크로만-4,7-디올 및 1-(4-하이드로페닐)-2-(피페리디닐-1)-알칸올 유도체 |
| JPH11512444A (ja) * | 1995-09-22 | 1999-10-26 | ノボ ノルディスク アクティーゼルスカブ | 新規置換アザ環式またはアザ二環式化合物 |
| US5900227A (en) * | 1996-06-17 | 1999-05-04 | Oklahoma Medical Research Foundation | Multicyclic nitrone spin trapping compositions |
| JP2002531456A (ja) * | 1998-11-27 | 2002-09-24 | ニューロサーチ、アクティーゼルスカブ | ８−アザビシクロ〔３．２．１〕オクト−２−エン及び−オクタン誘導体 |
| TW593223B (en) | 2000-06-20 | 2004-06-21 | Merz Pharma Gmbh & Co Kgaa | 1-amino-alkylcyclohexanes as 5-HT3 and neuronal nicotinic receptor antagonists |
| US6951961B2 (en) * | 2002-05-17 | 2005-10-04 | Marina Nikolaevna Protopopova | Methods of use and compositions for the diagnosis and treatment of infectious disease |
-
2003
- 2003-03-17 TW TW092105796A patent/TW200306189A/zh unknown
- 2003-03-18 AR ARP030100948A patent/AR039008A1/es unknown
- 2003-03-21 GE GEAP8454A patent/GEP20063954B/en unknown
- 2003-03-21 AU AU2003216855A patent/AU2003216855B2/en not_active Ceased
- 2003-03-21 MX MXPA04007755A patent/MXPA04007755A/es not_active Application Discontinuation
- 2003-03-21 UA UA20041008550A patent/UA77778C2/uk unknown
- 2003-03-21 JP JP2003577874A patent/JP4262606B2/ja not_active Expired - Fee Related
- 2003-03-21 US US10/394,670 patent/US7022729B2/en not_active Expired - Fee Related
- 2003-03-21 EP EP03712394A patent/EP1485086A1/en not_active Withdrawn
- 2003-03-21 CN CNA038044900A patent/CN1638762A/zh active Pending
- 2003-03-21 PL PL03372701A patent/PL372701A1/xx not_active Application Discontinuation
- 2003-03-21 KR KR1020047011982A patent/KR100741257B1/ko not_active Expired - Fee Related
- 2003-03-21 WO PCT/GB2003/001236 patent/WO2003080046A1/en not_active Ceased
- 2003-03-21 IL IL16404103A patent/IL164041A0/xx unknown
- 2003-03-21 CA CA002474637A patent/CA2474637A1/en not_active Abandoned
- 2003-03-21 EA EA200401230A patent/EA007098B1/ru unknown
-
2004
- 2004-08-31 ZA ZA200406940A patent/ZA200406940B/en unknown
- 2004-08-31 CO CO04085290A patent/CO5611104A2/es not_active Application Discontinuation
- 2004-10-20 NO NO20044481A patent/NO20044481L/no not_active Application Discontinuation
-
2005
- 2005-08-11 US US11/202,012 patent/US7238703B2/en not_active Expired - Fee Related
- 2005-08-11 US US11/202,115 patent/US20060019983A1/en not_active Abandoned
-
2007
- 2007-04-04 US US11/732,764 patent/US20070185151A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010505958A5 (https=) | ||
| JP2013526544A5 (https=) | ||
| JP2009504748A5 (https=) | ||
| AR070570A2 (es) | Compuesto de arilvinilazacicloalcano, una composicion farmaceutica que lo comprende y su uso en el tratamiento de enfermedades mediadas por alfa4beta2 nachr. | |
| JP2009538853A5 (https=) | ||
| JP7034935B2 (ja) | ピロロ［１，２－ａ］ピリミジニルカルボキサミド化合物および医学的障害の処置におけるその使用 | |
| HRP20151250T1 (hr) | Derivati izoksazolo-piridina | |
| JP2005525385A5 (https=) | ||
| TR201904614T4 (en) | Novel pyrazole derivative. | |
| JP2020502092A5 (https=) | ||
| WO2015191506A3 (en) | Pyrrolo[2,3-c]pyridines as imaging agents for neurofibrilary tangles | |
| IL189512A0 (en) | Neurorestoration with r(+)pramipexole | |
| JP2012526736A5 (https=) | ||
| JP2005518411A (ja) | 中枢神経系の障害を治療する製薬組成物及び方法 | |
| JP2008545793A5 (https=) | ||
| JP2006507220A5 (https=) | ||
| JP2005508381A5 (https=) | ||
| JP2019516739A5 (https=) | ||
| RU2012128583A (ru) | 3,6-диазабицикло[3.1.1]гептаны в качестве лигандов нейрональных никотиновых ацетилхолиновых рецепторов | |
| RS60556B1 (sr) | Kondenzovani benzazepini za lečenje mucanja | |
| US20180244623A1 (en) | N-methyl-D-aspartate Receptor (NMDAR) Potentiators, Pharmaceutical Compositions, And Uses Related Thereto | |
| JP2009511525A5 (https=) | ||
| MY142431A (en) | Oxadiazolones, processes for their preparation and their use as pharmaceuticals | |
| JP2005524696A5 (https=) | ||
| JP2020507592A5 (https=) |